Completed PHASE2 INTERVENTIONAL NCT00005853

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc

Sponsor: Fred Hutchinson Cancer Center

Conditions Leukemia Myelodysplastic Syndromes

Interventions anti-thymocyte globulin etanercept

Updated 6 times since 2017 Last updated: Mar 31, 2010 Started: Dec 31, 1999 Primary completion: Aug 31, 2005 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Leukemia and Myelodysplastic Syndromes and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States